<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04561830</url>
  </required_header>
  <id_info>
    <org_study_id>IR 180033-7</org_study_id>
    <nct_id>NCT04561830</nct_id>
  </id_info>
  <brief_title>Open or Laparoscopic Mesolectal Excision in Low Rectum Cancer</brief_title>
  <official_title>Total Mesorectal Resection With Dissection of the Lateral Pelvic Lymph Nodes in Low Advanced Cancer Rectum Patients; Laparoscopic Versus Open Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the open approach and the laparoscopic-assisted approach of dissection of lateral&#xD;
      lymph nodes in low advanced rectal cancer patients with clinically suspected nodal metastases&#xD;
      in terms of safety, technical feasibility, and patient's oncological outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the investigators collected data of sixty low advanced cancer rectum patients who underwent&#xD;
      either laparoscopic (30 cases) or open total mesorectal excision (30 cases) in addition to&#xD;
      lateral pelvic dissection. The duration of operation in the laparoscopically assisted&#xD;
      procedure was longer than the open procedure (p=0.003). The postoperative hospital stay time&#xD;
      was longer in the open group than in the laparoscopic group (P=0.043). No significant&#xD;
      differences between both groups regarding the number of excised lymph nodes, disease&#xD;
      recurrence, RFS, or OS rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">May 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>operative time</measure>
    <time_frame>during operative time</time_frame>
    <description>time of surgery in minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>operative complication</measure>
    <time_frame>durning operative time</time_frame>
    <description>bleed-injury of organs -failed procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>feasibility of procedure</measure>
    <time_frame>operative time</time_frame>
    <description>easy or difficult</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>post operative morbidity</measure>
    <time_frame>5 years</time_frame>
    <description>early and late complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>5 years</time_frame>
    <description>number of deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>recurrent cases</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>underwent laparoscopic-assisted excision of mesorectum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>open excision of mesorectum</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparoscopic-assited excision of mesorectum with pelvic lymph nodes excision</intervention_name>
    <description>We performed laparoscopic dissection of the lateral pelvic lymph node for thirty patients while we performed open lateral pelvic lymph node dissection for the remaining thirty patients.&#xD;
Performed surgical approaches were abdominoperineal resection, internal sphincter resection, and low anterior resection. All performed surgical procedures included lateral pelvic lymphadenectomy in addition to performing total mesorectal excision.&#xD;
Choosing whether to perform unilateral or bilateral lymphadenectomy depends on lymph nodes invasion by cancer was on one side or both sides.</description>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
    <other_name>open excision of mesorectum with pelvic Lymph nodes excision</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged from 20-70 years with&#xD;
&#xD;
          -  Sure diagnosis of locally advanced (T3 and T4) adenocarcinoma located in the middle or&#xD;
             lower part of the rectum&#xD;
&#xD;
          -  Clinical or radiological evidence of lateral pelvic lymph nodes metastases&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients refused to be included in the study,&#xD;
&#xD;
          -  Patients with concurrent primary cancer in other locations&#xD;
&#xD;
          -  Patients with recurrent cancer after treatment&#xD;
&#xD;
          -  Patients with distant metastasis&#xD;
&#xD;
          -  Previously managed for pelvic cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>September 19, 2020</last_update_submitted>
  <last_update_submitted_qc>September 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>osama khalil</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

